Septerna (NASDAQ:SEPN) Coverage Initiated at HC Wainwright

Investment analysts at HC Wainwright assumed coverage on shares of Septerna (NASDAQ:SEPN - Get Free Report) in a report released on Monday,Benzinga reports. The brokerage set a "buy" rating and a $26.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 148.33% from the stock's current price.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald raised their target price on shares of Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Wells Fargo & Company raised their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $26.75.

Septerna Trading Down 0.2%

Shares of NASDAQ:SEPN opened at $10.47 on Monday. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The firm's 50 day moving average price is $8.47 and its 200-day moving average price is $11.70.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter. As a group, analysts predict that Septerna will post -7.11 EPS for the current fiscal year.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in shares of Septerna in the fourth quarter worth about $25,000. New York State Common Retirement Fund bought a new stake in Septerna in the 4th quarter worth approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna during the 4th quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new position in shares of Septerna during the 4th quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna in the fourth quarter valued at $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.